RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
12.28
+0.58 (4.96%)
At close: Jul 22, 2025, 4:00 PM
12.28
0.00 (0.00%)
After-hours: Jul 22, 2025, 7:24 PM EDT

Company Description

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.

The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.

The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.

RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

RAPT Therapeutics, Inc.
RAPT Therapeutics logo
CountryUnited States
Founded2015
IPO DateOct 31, 2019
IndustryBiotechnology
SectorHealthcare
Employees68
CEOBrian Wong

Contact Details

Address:
561 Eccles Avenue
South San Francisco, California 94080
United States
Phone650-489-9000
Websiterapt.com

Stock Details

Ticker SymbolRAPT
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$12.00
CIK Code0001673772
CUSIP Number75382E109
ISIN NumberUS75382E1091
Employer ID47-3313701
SIC Code2834

Key Executives

NamePosition
Dr. Brian Russell Wong M.D., Ph.D.Chief Executive Officer, President and Director
Rodney K. B. YoungChief Financial Officer, Principal Accounting Officer and Secretary
Dr. William Ho M.D., Ph.D.Chief Medical Officer
Steve Young Ph.D.Vice President of Technology
Dr. Dirk G. Brockstedt Ph.D.Chief Scientific Officer
Michael ListgartenGeneral Counsel
Gwen R. CarscaddenChief Human Resources Officer
Dr. Paul Kassner Ph.D.Senior Vice President of Biology
Jennifer NicholsonSenior Vice President of Regulatory Affairs and Quality Assurance
Dr. Nipun Davar MBA, Ph.D.Senior Vice President of Technical Operations

Latest SEC Filings

DateTypeTitle
Jul 8, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
Jun 20, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 17, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 28, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report